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Loss of function studies have implicated cell-
intrinsic  factors  such  as  p21  (Cheng  et  al., 
2000), GFI1 (Hock et al., 2004), and LNK 
(Buza-Vidas et al., 2006) as physiological nega-
tive  regulators  of  hematopoietic  stem  cell 
(HSC) maintenance. Several extrinsic factors, 
including TGF- (Larsson and Karlsson, 2005), 
IFN- (Yang et al., 2005), and IL-3 (Yonemura 
et al., 1996), as well TNF (Bryder et al., 2001; 
Dybedal et al., 2001), have been demonstrated 
to negatively affect HSC growth and mainte-
nance in vitro. However, the in vivo relevance 
of these cytokines, as nonredundant cell-extrinsic 
endogenous  negative  regulators  of  the  HSC 
compartment, has not been strongly supported 
through in vivo lack of function studies (Seita 
and Weissman, 2010).
TNF, a pleiotropic cytokine exerting both 
inhibitory and stimulatory effects on a diversity 
of  cellular  processes,  is  a  key  regulator  of   
immunological responses, and aberrant pro-
duction of TNF underlies the pathogenesis of   
many human diseases, in particular acute and   
chronic inflammatory diseases (Bradley, 2008), 
for which TNF-blocking agents have become 
an  established  treatment  (Wiedmann  et  al., 
2009). Also, several BM failure syndromes such 
as Fanconi anemia (Dufour et al., 2003; Milsom 
et  al.,  2009)  are  associated  with  TNF  over-
expression (Bagby and Meyers, 2007). TNF signals 
through two distinct TNF receptors, Tnfrsf1a 
(TNF receptor super family 1a; or TNFR-p55) 
and Tnfrsf1b (or TNFR-p75; Aggarwal, 2003), 
that have been ascribed largely diverging roles. 
Apart from TNF and lymphotoxin (or TNF-), 
no other ligands have been shown to activate 
the TNF receptors (Aggarwal, 2003). Tnfrsf1a 
has an intracellular death domain implicated in 
apoptosis signaling, whereas Tnfrsf1b has often 
been implicated in the promotion of cellu-
lar proliferation (Aggarwal, 2003). However, 
mechanisms of cross talking, including ligand 
passing between Tnfrsf1a and Tnfrsf1b receptors 
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Whereas maintenance of hematopoietic stem cells (HSCs) is a requisite for life, uncon-
trolled expansion of HSCs might enhance the propensity for leukemic transformation. 
Accordingly, HSC numbers are tightly regulated. The identification of physical cellular HSC 
niches has underscored the importance of extrinsic regulators of HSC homeostasis. How-
ever, whereas extrinsic positive regulators of HSCs have been identified, opposing extrinsic 
repressors of HSC expansion in vivo have yet to be described. Like many other acute and 
chronic inflammatory diseases, bone marrow (BM) failure syndromes are associated with 
tumor necrosis factor-a (TNF) overexpression. However, the in vivo relevance of TNF in the 
regulation of HSCs has remained unclear. Of considerable relevance for normal hemato-
poiesis and in particular BM failure syndromes, we herein demonstrate that TNF is a cell-
extrinsic and potent endogenous suppressor of normal HSC activity in vivo in mice. These 
effects of TNF involve two distinct TNF receptors.
© 2011 Pronk et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months it 
is available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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(enriched for multipotent stem and progenitor cells; Fig. 2 f) 
mimicked the increased multilineage peripheral blood (PB) 
reconstitution levels (Fig. 2, b and d), supporting the idea that 
the suppressive effect of TNF is targeted to multipotent 
HSCs. Although we did not specifically address the homing of 
HSCs, altered HSC homing as a consequence of TNF recep-
tor deficiency is unlikely to explain the increased long-term 
reconstitution, as short-term (3 wk) reconstitution levels were 
unaffected in recipients of Tnfrsf1-dKO BM cells (Fig. 2 b).
TNF-mediated suppression of HSC activity is dependent  
on expression of both TNF receptors
As previous studies of the specific hematopoietic actions of 
TNF  mediated  through  Tnfrsf1a  and  Tnfrsf1b  have  been 
conflicting (Zhang et al., 1995; Rebel et al., 1999), we next 
evaluated the consequence of loss of either of the two TNF 
receptors  by  studying  mice  deficient  for  either  Tnfrsf1a   
(Tnfrsf1a/) or Tnfrsf1b (Tnfrsf1b/) receptors. Notably, we 
observed a competitive multilineage PB and BM LSK recon-
stitution advantage of BM cells from Tnfrsf1a/ (Fig. 2,   
g and i) as well as Tnfrsf1b/ (Fig. 2, h and j) mice. This ad-
vantage was sustained after secondary transplantations (Fig. 2, 
g–j),  although  the  competitive  advantage  was  more  pro-
nounced with BM cells from Tnfrsf1-dKO mice (Fig. 2, a–f), 
implicating the importance of both TNF receptors in restrict-
ing HSC expansion.
We next undertook a series of in vitro experiments to try 
to corroborate the requirement of both TNF receptors for 
the observed TNF-induced restriction of HSC activity. As 
expected, the clonal growth of WT BM cells was strongly 
inhibited in response to TNF (Fig. 3, a–c). Notably, TNF 
had no discernable effect on the clonal growth of different 
myeloerythroid progenitors from Tnfrsf1a/ or Tnfrsf1b/ 
mice (Fig. 3, a–c), and the same observation was made with 
regard to the effect of TNF on the growth of HSC-enriched 
LSK cells (Fig. 3 d), which is compatible with both Tnfrsf1a 
and  Tnfrsf1b  being  required  for  the  suppressive  effects   
of TNF on HSCs and hematopoiesis. Importantly, TNF-
  mediated growth inhibition could not be rescued in cells over-
expressing the antiapoptotic protein BCL2 (Fig. S1, a–c; Domen 
et al., 1998), suggesting that induction of apoptosis plays little 
or  no  role  in  TNF-induced  growth  inhibition  and  HSC   
expansion. However, as these experiments were performed 
in vitro and as there are alternative, BCL2-resistant pathways 
for apoptosis, we cannot rule out the possibility that the sup-
pressive effects of TNF on HSCs might involve apoptosis.
In vivo administration of TNF targets HSCs
Although no other ligands than TNF and TNF- are known 
for the two TNF receptors, we could not rule out the possi-
bility that the HSC phenotype in Tnfrsf1a/ and Tnfrsf1b/ 
mice is not mediated by TNF. Thus, we next investigated 
the effects of TNF administered in vivo on HSCs. Further-
more, as the suppressive impact of TNF on HSC activity   
after transplantation but not in steady-state hematopoiesis could 
in part be related to HSCs being recruited from quiescence 
(Tartaglia et al., 1993), implicate that some functions of TNF 
might be facilitated by or even strictly depend on the expres-
sion of both receptors, although evidence for this is limited.
The physiological relevance of the ability of TNF to sup-
press mouse and human HSC maintenance in vitro (Zhang   
et al., 1995; Bryder et al., 2001; Dybedal et al., 2001) can 
rightfully be questioned, among other reasons because the 
investigated concentrations of TNF might be physiologically 
irrelevant, because TNF exists in two isoforms (TNF and 
TNF-; Aggarwal, 2003), and because the in vitro experi-
ments could not mimic the physiological balance and poten-
tially distinct roles of soluble and membrane-bound TNF   
in vivo (Grell et al., 1995). Furthermore, TNF is likely to have 
pleiotropic direct and indirect effects on HSCs in vivo. In 
fact, previous in vivo TNF loss of function experiments did 
not only fail to support a suppressive role of TNF in HSC 
regulation, they rather implicated a stimulatory role of TNF 
in HSC maintenance in vivo (Rebel et al., 1999), in apparent 
discrepancy with studies demonstrating a potent suppressive 
effect of TNF on normal HSCs in vitro (Bryder et al., 2001; 
Dybedal et al., 2001), as well as HSCs in Fanconi anemia 
models for BM failure syndromes being hyperresponsive to 
TNF suppression in vitro (Milsom et al., 2009). Herein, we 
sought to reconcile these previous findings and to establish 
the in vivo role of TNF in the regulation of HSC mainte-
nance and expansion in mice lacking expression of either or 
both TNF receptors.
RESULTS AND DISCUSSION
TNF restricts HSC activity in vivo
We first investigated HSC numbers and function in mice   
deficient  for  both  Tnfrsf1a  (Tnfrsf1a/)  and  Tnfrsf1b   
(Tnfrsf1b/) receptors, hereafter referred to as Tnfrsf1 double 
KO (Tnfrsf1-dKO; Peschon et al., 1998). Unlike previous 
studies of Tnfrsf1a/ mice (Zhang et al., 1995; Rebel et al., 
1999), we did not observe any differences in phenotypically 
enriched HSCs (LSKFLT3; Fig. 1, b and c; Adolfsson et al., 
2001) nor in frequencies of long-term reconstituted mice 
when unfractionated BM cells were transplanted at limiting 
numbers from steady-state BM of WT and Tnfrsf1-dKO  
(Fig. 1 d), suggesting that HSCs are not affected by TNF in 
steady-state. Steady-state cell cycle analyses of cells within the 
LSKFLT3  HSC-enriched  compartment  revealed  only  a   
minor increase of cells in active cell cycle (G1 and S/G2/M) in 
Tnfrsf1-dKO mice as compared with WT mice, and in both 
cases LSKFLT3 cells were predominantly found to be highly 
quiescent (Fig. 1, e and f).
In contrast to the steady-state analysis, Tnfrsf1-dKO BM 
cells revealed a considerable competitive advantage over WT 
BM cells in their ability to long-term reconstitute myeloid 
and lymphoid cell lineages in myeloablated WT recipients 
(Fig. 2, a–f). This competitive advantage of Tnfrsf1-dKO BM 
cells was further enhanced after three rounds of serial trans-
plantation and maintained for a total of at least five rounds of 
transplantation (Fig. 2 b). An enhanced Tnfrsf1-dKO donor 
contribution to the phenotypically defined LSK compartment JEM Vol. 208, No. 8  1565
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induced a reduction in total BM cellularity (Fig. 4 b) and a 
reduction in HSC activity as determined in a competitive 
transplantation assay (Fig. 4, c–f). This suppressive effect of 
TNF on HSC activity was enhanced in 5-FU–treated mice 
(Fig.  4,  b–f).  These  findings  suggest  that  actively  cycling 
rather than quiescent HSCs are the primary targets of TNF 
suppression, which is of relevance for the enhanced reconsti-
tution after transplantation.
This study provides the first in vivo evidence of a non-
redundant, cell-extrinsic factor involved in negative regulation 
of the HSC compartment, specifically in a setting relevant for 
BM transplantation. Importantly, our experiments of mice 
into active proliferation upon transplantation (Allsopp et al., 
2001), we also sought to address the effect of TNF on cycling 
versus quiescent HSCs. Of relevance, we previously reported 
that HSCs up-regulate cell surface expression of TNF recep-
tors and become TNF responsive upon ex vivo proliferation 
(Bryder et al., 2001). To address whether cell cycle activation 
also enhances TNF-induced suppression of HSCs in vivo, we 
took advantage of the cytotoxic drug 5-fluorouracil (5-FU), 
which effectively eliminates cycling hematopoietic progeni-
tors but not HSCs, resulting in rapid recruitment of dormant 
HSCs into active proliferation (Harrison and Lerner, 1991). 
TNF treatment of adult WT steady-state mice (Fig. 4 a)   
Figure 1.  HSC numbers are normal in steady-state adult BM of Tnfrsf1-dKO mice. (a) In six separate experiments with three mice in each experi-
ment, BM cells from two tibiae and two femurs per mouse were individually isolated from age (8–12 wk old)- and sex-matched WT (n = 18) and Tnfrsf1-dKO 
(n = 18) mice, and mean (SD) cellularities were determined. (b and c) In two separate experiments, age (8–12 wk old)- and sex-matched adult WT C57BL/6 and 
Tnfrsf1-dKO mice, five of each genotype, were analyzed individually for frequencies of LSKFLT3 cells by FACS. (b) Representative FACS analysis for each of 
the genotypes. Displayed percentages of population frequencies of total BM cells are mean values for five mice in each group, each mouse analyzed individu-
ally. (c) BM cell numbers and absolute numbers of LSKFLT3 cells were determined for each mouse individually (see Materials and methods). Mean (SD) values 
of five mice are shown. (d) In two separate experiments with 14 recipients in each, 20,000 unfractionated BM cells from either WT (CD45.1+/2+) or Tnfrsf1-
dKO (CD45.1/2+) mice were transplanted, together with 200,000 competitor BM cells (CD45.1+/2), into lethally irradiated congenic WT recipients 
(CD45.1+/2). 16 wk after transplantation, recipients were analyzed individually for multilineage reconstitution. The percentage of PB donor myeloid reconsti-
tution in positively reconstituted mice is indicated. Horizontal lines represent median reconstitution levels. The frequencies of reconstituted mice (as defined 
in Materials and methods) out of total transplanted mice are indicated. The indicated p-value is for difference in mean donor reconstitution levels of mice 
transplanted with Tnfrsf1-dKO and WT BM cells. (e and f) CD45.1+ BM cells from four WT mice and CD45.2+ BM cells from four Tnfrsf1-dKO mice were indi-
vidually isolated, and subsequently cells from each of the WT replicates were mixed with cells from one of the Tnfrsf1-dKO mice. Cells from each genotype 
were mixed at equal numbers, and each cell mixture was analyzed individually. Cell mixtures were analyzed by FACS for G0 (DAPIlow/Ki67), G1 (DAPIlow/Ki67+), 
and S/G2/M (DAPIhigh/Ki67+) cell cycle stages within the LSKFLT3 HSC compartment. Percentages represent mean (SD) values of all mice.1566 TNF restricts HSC activity in vivo | Pronk et al.
Figure 2.  Enhanced activity of TNF receptor–deficient HSCs after transplantation. (a–f) BM cells were pooled from three Tnfrsf1-dKO (CD45.2+) or three WT 
(CD45.1+) mice (8–12 wk old), and for each of the genotypes 106 unfractionated BM cells were competitively cotransplanted into lethally irradiated congenic WT re-
cipients (CD45.1+/2+). Recipient mice were evaluated for PB multilineage reconstitution levels at the indicated time points. (a) Representative FACS analysis illustrating 
PB myeloid chimerism evaluation. (b) PB myeloid reconstitution derived from transplanted Tnfrsf1-dKO and WT cells was analyzed at the indicated time points. At  
the time points indicated by the vertical dashed lines, mice were sacrificed, and 0.5 femur equivalent of BM cells were serially transplanted into newly irradiated 
(CD45.1+/2+) recipients. Displayed are PB myeloid chimerism levels. Results are mean (SEM) values from six separate experiments with five to seven recipients in each 
experiment. (c–f) 16 wk after the primary transplantation, PB analysis of T (CD4/CD8), myeloid (MAC1), and B (B220) cell reconstitution was performed (d), BM was 
analyzed for LSK chimerism (f), and mean percentages for all recipients are presented. (c and e) Representative FACS analysis for reconstitution levels within the PB 
and BM are shown. (d and f) Results are from six separate experiments with five to seven recipients in each experiment. Mean (SEM) values are shown. (g–j) BM cells 
from 8–12 wk old Tnfrsf1a/ (g and i) and Tnfrsf1b/ (h and j) mice (CD45.2+, backcrossed for 10 generations with C57BL/6 mice) were transplanted in competition 
with WT BM cells (CD45.1+) into lethally irradiated WT (CD45.1+/2+) recipients. PB myeloid chimerism levels (g and h) and BM LSK chimerism levels (i and j) at the indi-
cated time points after primary and secondary (indicated by dashed line) transplantations are shown. All results are mean (SEM) values from two separate experiments 
with five to seven recipients in each experiment. PB and BM reconstitution analysis were performed as illustrated in panels a and e, respectively.JEM Vol. 208, No. 8  1567
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HSCs, either through signaling through both receptors or 
potentially through the suggested role of the Tnfrsf1b in ligand 
passing to the Tnfrsf1a receptor (Aggarwal, 2003).
The current findings are of considerable relevance for   
several BM failure syndromes, in which enhanced expression 
of TNF  has  been  implicated  in  the 
pathogenesis of hematopoietic failure 
deficient in Tnfrsf1a or Tnfrsf1b expression, corroborated by 
in vitro TNF response experiments, indicate that the ability 
of TNF to suppress HSCs is dependent on expression of both 
TNF  receptors.  This  clearly  implicates  the  importance  of 
both receptors in eliciting the signaling required to suppress 
Figure 3.  TNF-mediated suppression  
in vitro is critically dependent on expres-
sion of both TNF receptors. (a) In four sepa-
rate experiments, with two replicates in each 
experiment, 20,000 whole BM cells from  
8–12-wk-old WT, Tnfrsf1-dKO, Tnfrsf1a/, and 
Tnfrsf1b/ mice (all backcrossed for 10 gen-
erations with C57BL/6 mice) were plated in 
methylcellulose supplemented with G-CSF and 
SCF in the presence and absence of TNF (±TNF). 
CFU-GM was scored after 7 d in culture. Mean 
(SD) values for all mice and experiments are 
shown. (b and c) 100,000 whole BM cells/dish 
were seeded in semisolid methylcellulose  
medium supplemented with SCF, erythropoietin, 
and thrombopoietin, ±TNF, and analyzed  
for erythroid (BFU-E) and megakaryocyte  
(CFU-Meg) colony potentials after 8 d in cul-
ture. Mean (SD) data from four methylcellulose 
replicates in two separate experiments are 
shown. (d) FACS-purified LSK cells from pooled 
mice of each indicated genotype were single cell sorted into Terasaki plates containing SCF and G-CSF, ±TNF. After 11 d of culture, the number of colonies 
(>50 cells) was scored. Mean (SD) values from two experiments with two replicate plates each and each plate containing 60 cells are shown.
Figure 4.  In vivo administration of TNF 
suppresses cycling HSCs. (a) Experimental 
design. Age (8–12 wk old)- and sex-matched 
C57BL/6 WT mice received 150 mg/kg 5-FU or 
PBS 3 d before intravenous injections of  
3 × 2 µg TNF or PBS. (b) BM cellularity in mice 
treated with PBS, PBS and TNF, 5-FU, or 5-FU 
and TNF. Mean (SD) values of three experi-
ments, each with three individual mice in 
each treatment group, are shown. (c–e) At  
day 0, 1/50 of unfractionated BM cells 
(CD45.2+) in two femurs and two tibias from 
treated mice in each of the indicated groups 
were transplanted in competition with 106 
unfractionated WT BM (CD45.1+) cells into 
congenic lethally irradiated WT recipients 
(CD45.1+/2+). 16 wk after transplantation, PB 
reconstitution levels were analyzed for per-
centage of CD45.2+ contribution within the  
T cell (c), B cell (d), and myeloid blood cell (e) 
lineages. (f) Bars show calculated numbers 
(see Materials and methods) of total CRUs in 
PBS-, PBS + TNF–, 5-FU–, and 5-FU + TNF–
treated donor BM cells based on PB levels of 
myeloid chimerism 16 wk after transplanta-
tion. (c–f) Results are mean (SD) values from 
three separate experiments, each with five to 
seven recipients/group.1568 TNF restricts HSC activity in vivo | Pronk et al.
followed by subsequent backcrossing for five generations to C57BL/6 mice. 
Tnfrsf1-dKO mice were used for phenotyping and competitive transplan-
tation experiments, with WT C57BL/6 mice (CD45.2+, CD45.1+, or F1 
CD45.1+/CD45.2+) as controls. Tnfrsf1a/ and Tnfrsf1b/ single KO mice 
were generated by crossing Tnfrsf1-dKO to WT C57BL/6 mice to create 
single KO mice with identical allelic mutations as the original Tnfrsf1a/ 
and Tnfrsf1b/ mice, respectively. Heterozygous offspring were interbred 
to generate Tnfrsf1a/ and Tnfrsf1b/ mice for in vitro experimentation 
(Fig. 3, a–d), and WT littermates were used as controls. Single KO mice 
were also backcrossed with C57BL/6 mice for an additional four genera-
tions to generate 10th generation Tnfrsf1a/ and Tnfrsf1b/ single KO mice. 
These mice were used in the transplantation experiments. H2K–BCL-2 mice 
have been described previously (Domen et al., 1998). Mice were main-
tained at the Lund University animal facility. All mice procedures were 
performed with consent from the local ethics committee (Malmö/Lunds   
djurförsöksetiska nämnd).
Phenotypic analysis and purification of HSCs. BM cells were collected 
from femurs, tibiae, and sometimes iliac crests. For both phenotypic analysis 
and FACS purification, unfractionated BM cells were stained with either 
purified or fluorochrome-conjugated lineage antibodies against B220 (RA3-
6B2), GR-1 (RB6-8C5), MAC1 (M1/70), CD8 (53–6.7), TER119, CD4 
(H129.19), and sometimes CD5 (53–7), all from BD. FACS purifications 
were performed as previously described (Adolfsson et al., 2001). In brief, 
cells were next either lineage depleted using sheep anti–rat IgG(Fc)–conjugated 
immunomagnetic  beads  (Invitrogen)  or  cKIT  enriched  by  using  cKit-
  conjugated magnetic beads (Miltenyi Biotec). Purified lineage antibodies were 
visualized with CyChrome (Invitrogen)- or Qdot 605 (Invitrogen)–conjugated 
goat anti–rat antibodies; in the case of lineage depletion, cells were stained 
after the lineage enrichment, and in the case of cKIT enrichment, cells were 
stained before magnetic selection. Subsequently, cells were stained with 
different combinations of fluorochrome-conjugated antibodies against SCA1 
(D7 [BioLegend] or E13-161.7 [BD]), cKIT (or CD117, 2B8; eBioscience 
or BD), FLT3 (or Flk2/CD135, 2F10.1; BD or eBioscience), and CD150 
(or Slamf1, TC15-12F12.2; BioLegend). Propidium iodide (Invitrogen) or 
7-amino-actinomycin D (Sigma-Aldrich) was used to exclude dead cells. 
Gating was performed to exclude doublets from analysis.
For calculation of total numbers of LSK and LSKFLT3 cells, the fre-
quency of LSKFLT3 cells in each individual mouse, as determined by flow 
cytometric evaluation of unfractionated BM cells, was multiplied by total 
BM cell numbers. Total BM numbers were calculated based on total BM 
cells in two femurs and two tibiae, representing 25% of total BM cells pres-
ent in a mouse. For cell cycle analyses (Thorén et al., 2008), 30 × 106 
CD45.1+ (WT) and 30 × 106 CD45.2+ (Tnfrsf1-dKO) BM cells were mixed 
and stained with antibodies against lineage markers, SCA1, cKIT, CD150, 
and FLT3 as described in the previous paragraph, as well as with antibodies 
against  CD45.1+  (A20;  BioLegend)  and  CD45.2+  (104;  BioLegend). 
Subsequently, cells were fixated in 2% paraformaldehyde (GTF) and per-
meabilized  in  0.1%  saponin  from  quillaja  bark  (Sigma-Aldrich)  and 
stained with anti-Ki67 (B56; BD) or isotype-conjugated antibodies. Before 
analysis, cells were incubated in 2.5 µg/ml DAPI (Invitrogen) to visualize 
DNA content.
Cells were analyzed or sorted on FACS Aria or DIVA cell sorters (BD). 
All flow cytometry and FACS data were analyzed with FlowJo software   
(Tree Star).
In vivo transplantation experiments. Competitive transplantation ex-
periments using the congenic CD45.1+/CD45.2+ mouse model were per-
formed as described previously (Szilvassy et al., 1990; Adolfsson et al., 2001). 
In brief, CD45.2+ BM cells from TNF receptor–deficient mice were in-
jected intravenously along with competitor CD45.1 BM cells into lethally 
irradiated (950 cGy) CD45.1+/2+ mice. PB was collected at the indicated 
time points after transplantation and analyzed for donor reconstitution by 
FACS. PB was obtained from retroorbital bleeding, red blood cells were 
sedimented with 2% dextran T-500 (Pharmacia), remaining red blood cells 
(Bagby and Meyers, 2007; Aalto et al., 2011). For instance, in 
the case of Fanconi anemia, TNF has not only been demon-
strated to be overexpressed in the BM (Dufour et al., 2003), 
but HSCs have also been found to be hyperresponsive to 
TNF suppression in vitro (Milsom et al., 2009). The physio-
logical relevance of these in vitro findings, as well as previous 
findings demonstrating that TNF has potent suppressive ef-
fects on WT mouse and human HSCs in vitro (Bryder et al., 
2001; Dybedal et al., 2001), are supported by our demonstra-
tion of a suppressive role of Tnfrsf1a and Tnfrsf1b on HSCs   
in vivo, as well as an HSC-suppressive effect of TNF adminis-
tration in vivo. The reason for the opposite conclusions reached 
in the experiments by Rebel et al. (1999) remains unclear. In 
that study, Tnfrsf1a was rather suggested to play a critical posi-
tive role in maintaining HSCs. This role of TNF appeared to 
be restricted to older mice (>6 mo old), although phenotypic 
analysis of the HSC compartment in older mice showed no 
significant difference from WT mice (Rebel et al., 1999). 
Thus, it was only in long-term transplantation experiments 
that reduced multilineage reconstitution was observed from 
Tnfrsf1a/ BM cells as an indication of reduced HSC activ-
ity (Rebel et al., 1999), although phenotypic analysis of the 
HSC compartment itself was not performed in transplanted 
mice. It is not obvious how the age of the TNF receptor– 
deficient HSCs could explain the different conclusions reached 
between this previous study and our study, as we in our study 
performed serial transplantation experiments for up to 76 wk 
with HSCs with an intrinsic TNF receptor deficiency. More-
over, in our study, the enhanced long-term multilineage re-
constitution levels of TNF receptor–deficient BM cells were 
corroborated by correspondingly enhanced chimerism also in 
the phenotypic HSC compartment. Although the mice used 
herein carry the same mutated alleles, the genetic background 
of the TNF receptor–deficient strains and the nature of the 
WT control mice were not described in detail in the study of 
Rebel et al. (1999), and therefore the apparent discrepancy 
could potentially be explained by this. In that regard, our study 
included experiments in which experimental mice had been 
backcrossed to a C57BL/6 genetic background and in which 
WT littermates were used as controls.
This study establishes the in vivo relevance of the sup-
pressive effects of TNF on HSCs in hematopoiesis and BM 
failure  syndromes  and  supports  the  further  exploration  of 
anti-TNF treatment in such conditions (Dufour et al., 2009; 
Scott et al., 2010; Aalto et al., 2011). The in vivo condition-
ing models used in this study, 5-FU treatment and irradia-
tion, have been shown to cause increases in blood levels of 
TNF (Xun et al., 1994; Okamoto et al., 2000), suggesting 
that anti-TNF treatment might also be beneficial to enhance 
posttransplantation reconstitution (Ferrara et al., 2009).
MATERIALS AND METHODS
Mice. Tnfrsf1-dKO mice (TNF receptor double KO; Peschon et al., 1998)   
were  obtained  from  the  Jackson  Laboratory  (stock  no.  003243). The   
Tnfrsf1-dKO mice were originally generated by interbreeding mice deficient 
for Tnfrsf1a (or Tnfr-p55, generated on a C57BL/6 background) with   
mice deficient for Tnfrsf1b (or Tnfr-p75, generated on a 129 background), JEM Vol. 208, No. 8  1569
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CD8, B220, MAC1, and NK1.1 (PK136; BioLegend).
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In in vivo TNF treatment experiments, WT (CD45.2+) were injected 
intravenously with 5-FU and/or recombinant mouse TNF (Genentech).   
After treatment, BM cells were isolated from two femurs and two tibiae and 
counted, and 1/50 of isolated BM cells (i.e., 1/200 of total mouse BM cells) 
were transplanted in competition with 106 fresh CD45.1+ BM into each   
lethally irradiated CD45.1+ recipient. The total number of CRUs present in a 
mouse after treatment was calculated as previously described (Szilvassy et al., 
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cells (Szilvassy et al., 1990), the competing graft (106 whole BM) contained 100 
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(% myeloid chimerism 16 wk after transplant)/(100%  % myeloid chimerism   
16 wk after transplant). The number of BM cells containing 1 CRU (Y) = (total 
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In vitro culture assays. Freshly isolated unfractionated BM cells and sorted 
HSC-enriched cells were cultured using liquid and semisolid culture condi-
tions (at 37°C, 98% humidity, and 5% CO2) to evaluate their colony-forming 
and clonogenic capacities. CFU-GM, BFU-E, and CFU-Meg formations 
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previously described (Adolfsson et al., 2001), and cells were cultured in the 
presence or absence of 20 ng/ml TNF in addition to the indicated cytokines. 
For evaluation of proliferative capacities, HSC-enriched cells were sorted 
into serum-free medium (X-vivo15; BioWhittaker), supplemented with 1% 
detoxified bovine serum albumin (STEMCELL Technologies), 0.1 mM   
-mercaptoethanol, 2 mM l-glutamine (Invitrogen), streptomycin/penicillin 
(Sigma-Aldrich), and cytokines rrSCF (25 ng/ml; Amgen or PeproTech), 
rhIL-6 (50 ng/ml; provided by Genetics Institute Cambridge, San Francisco, 
CA), and rmIL3 (20 ng/ml; PeproTech), with or without 20 ng/ml TNF. 
After 7 d of culture, total cell numbers were counted, and expansion equiva-
lents were calculated. For evaluation of clonogenic capacity, HSC-enriched 
cells were single cell sorted in Terasaki plates into IMDM, supplemented 
with 10% prescreened FCS (Invitrogen), -mercaptoethanol, l-glutamine, 
and streptomycin/penicillin as above, with the addition of 25 ng/ml rrSCF 
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Statistics. Statistical analyses were performed using Excel software (Micro-
soft). Student’s t test was used to generate all p-values.
Online supplemental material. Fig. S1 shows clonogenic capacities of 
HSCs sorted from WT or Bcl2 transgenic mice cultured in the presence and 
absence of TNF. Online supplemental material is available at http://www 
.jem.org/cgi/content/full/jem.20110752/DC1.
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